Interleukin‑1 receptor‑associated kinase 4 as a potential biomarker: Overexpression predicts poor prognosis in patients with glioma

Wang,Jialin; Wang,Jialin; Liu,Binfeng; Liu,Binfeng; Yao,Jiawei; Yao,Jiawei; Liu,Zhendong; Liu,Zhendong; Wang,Hongbo; Wang,Hongbo; Zhang,Bo; Zhang,Bo; Lian,Xiaoyu; Lian,Xiaoyu; Ren,Zhishuai; Ren,Zhishuai; Liu,Liyun; Liu,Liyun; Gao,Yanzheng; Gao,Yanzheng

doi:10.3892/ol.2021.12516

Interleukin‑1 receptor‑associated kinase 4 as a potential biomarker: Overexpression predicts poor prognosis in patients with glioma

Authors:
- Jialin Wang
- Binfeng Liu
- Jiawei Yao
- Zhendong Liu
- Hongbo Wang
- Bo Zhang
- Xiaoyu Lian
- Zhishuai Ren
- Liyun Liu
- Yanzheng Gao
View Affiliations

Affiliations: Department of Orthopaedics, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, Henan 450001, P.R. China, Department of Neurosurgery, First Affiliated Hospital of Harbin Medical University and Institute of Brain Science, Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Orthopaedics, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou, Henan 450001, P.R. China, Department of Orthopaedics, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, Henan 450001, P.R. China
Published online on: February 3, 2021 https://doi.org/10.3892/ol.2021.12516
Article Number: 254
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The undetectable onset of glioma and the difficulty of surgery lead to a poor prognosis. Appropriate biomarkers for diagnosis and treatment need to be identified. Interleukin‑1 receptor‑associated kinase 4 (IRAK4) is involved in the initiation and progression of cancer. However, up until now, no report has revealed the relationship between IRAK4 and glioma. The present study aimed to examine the expression of IRAK4 in glioma, and to determine if there was a relationship between IRAK4 expression and clinical outcomes or survival prognosis. Thousands of glioma tissue samples and corresponding clinical information were obtained from various databases. Then a series of bioinformatics methods were used to reveal the role of IRAK4 in glioma. Finally, reverse transcription‑quantitative PCR technology was used to verify the bioinformatics results. The study found that the expression of IRAK4 was significantly increased in glioma compared with the control brain tissue samples, and IRAK4, as an independent prognostic factor, shortened the overall survival time of patients with glioma. Gene Set Enrichment Analysis showed that IRAK4 promoted the activation of cell signalling pathways, such as NOD‑like and Toll‑like receptor signalling pathways. Co‑expression analysis showed that the expression of IRAK4 was correlated with CMTM6, MOB1A and other genes. The present study demonstrated the role of IRAK4 as an oncogene in the pathological process of glioma for the first time, and highlights the potential of IRAK4 as a biomarker for prognostic evaluation and treatment of glioma.

View Figures

View References

1	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
2	Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F and Franceschi E: Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology. Neuro Oncol. 10:361–367. 2008. View Article : Google Scholar : PubMed/NCBI
3	Ho VK, Reijneveld JC, Enting RH, Bienfait HP, Robe P, Baumert BG and Visser O; Dutch Society for Neuro-Oncology (LWNO), : Changing incidence and improved survival of gliomas. Eur J Cancer. 50:2309–2318. 2014. View Article : Google Scholar : PubMed/NCBI
4	Kargbo RB: PROTAC degradation of IRAK4 for the treatment of cancer. ACS Med Chem Lett. 10:1370–1371. 2019. View Article : Google Scholar : PubMed/NCBI
5	Li Q, Chen Y, Zhang D, Grossman J, Li L, Khurana N, Jiang H, Grierson PM, Herndon J, DeNardo DG, et al: IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer. JCI Insight. 4:e1308672019. View Article : Google Scholar
6	Cheng BY, Lau EY, Leung HW, Oi-Ning Leung C, Ho NP, Gurung S, Cheng LK, Lin CH, Cheuk-Lam Lo R, Ma S, et al: IRAK1 augments cancer stemness and drug resistance via the AP-1/AKR1B10 signaling cascade in hepatocellular carcinoma. Cancer Res. 78:2332–2342. 2018. View Article : Google Scholar : PubMed/NCBI
7	Zhang D, Li L, Jiang H, Knolhoff BL, Lockhart AC, Wang-Gillam A, DeNardo DG, Ruzinova MB and Lim KH: Constitutive IRAK4 activation underlies poor prognosis and chemoresistance in pancreatic ductal adenocarcinoma. Clin Cancer Res. 23:1748–1759. 2017. View Article : Google Scholar : PubMed/NCBI
8	Wang Z, Wang Z, Zhang C, Liu X, Li G, Liu S, Sun L, Liang J, Hu H, Liu Y, et al: Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma. Cancer Sci. 109:2697–2705. 2018. View Article : Google Scholar : PubMed/NCBI
9	Tomczak K, Czerwińska P and Wiznerowicz M: The cancer genome atlas (TCGA): An immeasurable source of knowledge. Contemp Oncol (Pozn). 19:A68–77. 2015.PubMed/NCBI
10	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
11	Suzuki A, Horie T and Numabe Y: Investigation of molecular biomarker candidates for diagnosis and prognosis of chronic periodontitis by bioinformatics analysis of pooled microarray gene expression datasets in gene expression omnibus (GEO). BMC Oral Health. 19:522019. View Article : Google Scholar : PubMed/NCBI
12	Grzmil M, Morin P Jr, Lino MM, Merlo A, Frank S, Wang Y, Moncayo G and Hemmings BA: MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma. Cancer Res. 71:2392–2402. 2011. View Article : Google Scholar : PubMed/NCBI
13	Griesinger AM, Birks DK, Donson AM, Amani V, Hoffman LM, Waziri A, Wang M, Handler MH and Foreman NK: Characterization of distinct immunophenotypes across pediatric brain tumor types. J Immunol. 191:4880–4888. 2013. View Article : Google Scholar : PubMed/NCBI
14	Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z and Edfors F: A pathology atlas of the human cancer transcriptome. Science. 357:eaan25072017. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
17	Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, et al: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 34:267–273. 2003. View Article : Google Scholar : PubMed/NCBI
18	Wang G, Bie F, Li G, Shi J, Zeng Y and Du J: Study of the co-expression gene modules of non-small cell lung cancer metastases. Cancer Biomark. Dec 3–2020.(Epub ahead of print). doi: 10.3233/CBM-201605. View Article : Google Scholar
19	Li X, Liu Z, Mi M, Zhang C, Xiao Y, Liu X, Wu G and Zhang L: Identification of hub genes and key pathways associated with angioimmunoblastic T-cell lymphoma using weighted gene co-expression network analysis. Cancer Manag Res. 11:5209–5220. 2019. View Article : Google Scholar : PubMed/NCBI
20	Chan BKC: Data analysis using R programming. Adv Exp Med Biol. 1082:47–122. 2018. View Article : Google Scholar : PubMed/NCBI
21	van Dam S, Vosa U, van der Graaf A, Franke L and de Magalhães JP: Gene co-expression analysis for functional classification and gene-disease predictions. Brief Bioinform. 19:575–592. 2018.PubMed/NCBI
22	Schwartzbaum JA, Fisher JL, Aldape KD and Wrensch M: Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2:494–503. 2006. View Article : Google Scholar : PubMed/NCBI
23	Komori T: The 2016 WHO classification of tumours of the central nervous system: The major points of revision. Neurol Med Chir (Tokyo). 57:301–311. 2017. View Article : Google Scholar : PubMed/NCBI
24	Chen R, Smith-Cohn M, Cohen AL and Colman H: Glioma subclassifications and their clinical significance. Neurotherapeutics. 14:284–297. 2017. View Article : Google Scholar : PubMed/NCBI
25	Apte RS, Chen DS and Ferrara N: VEGF in signaling and disease: Beyond discovery and development. Cell. 176:1248–1264. 2019. View Article : Google Scholar : PubMed/NCBI
26	Yunker CK, Golembieski W, Lemke N, Schultz CR, Cazacu S, Brodie C and Rempel SA: SPARC-Induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion. Int J Cancer. 122:2735–2743. 2008. View Article : Google Scholar : PubMed/NCBI
27	Tu Y, Zhong Y, Fu J, Cao Y, Fu G, Tian X and Wang B: Activation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomas. Med Oncol. 28:15–23. 2011. View Article : Google Scholar : PubMed/NCBI
28	Zhang P, Chen FZ, Jia QB and Hu DF: Upregulation of microRNA-133a and downregulation of connective tissue growth factor suppress cell proliferation, migration, and invasion in human glioma through the JAK/STAT signaling pathway. IUBMB Life. 71:1857–1875. 2019. View Article : Google Scholar : PubMed/NCBI
29	Kumar DM, Patil V, Ramachandran B, Nila MV, Dharmalingam K and Somasundaram K: Temozolomide-Modulated glioma proteome: Role of interleukin-1 receptor-associated kinase-4 (IRAK4) in chemosensitivity. Proteomics. 13:2113–2124. 2013. View Article : Google Scholar : PubMed/NCBI
30	Sloan KE, Stewart JK, Treloar AF, Matthews RT and Jay DG: CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res. 65:10930–10937. 2005. View Article : Google Scholar : PubMed/NCBI
31	Zheng Y, Miu Y, Yang X, Yang X and Zhu M: CCR7 Mediates TGF-beta1-induced human malignant glioma invasion, migration, and epithelial-mesenchymal transition by activating MMP2/9 through the nuclear factor KappaB signaling pathway. DNA Cell Biol. 36:853–861. 2017. View Article : Google Scholar : PubMed/NCBI
32	Luo J, Solimini NL and Elledge SJ: Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell. 136:823–837. 2009. View Article : Google Scholar : PubMed/NCBI
33	Takada K, Kohashi K, Shimokawa M, Haro A, Osoegawa A, Tagawa T, Seto T, Oda Y and Maehara Y: Co-Expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy. Lung Cancer. 128:26–32. 2019. View Article : Google Scholar : PubMed/NCBI
34	Guan X, Zhang C, Zhao J, Sun G, Song Q and Jia W: CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. EBioMedicine. 35:233–243. 2018. View Article : Google Scholar : PubMed/NCBI